Clearside explores strategic alternatives; all employees terminated, R&D paused

Clearside Biomedical, Inc.

All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.
Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.
Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.
No agreement reached; no timetable set; no assurance any transaction will occur.
CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners.

item 2.05item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.